Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The company expects revenue growth of 10-15 per cent in the US
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated